Brown, Philip M <br/><br/>
The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.  [electronic resource] 

 -  Gastroenterology  Aug 2011 
 - 507-16 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2011.05.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--etiology<br/>Adult<br/>Biomarkers--urine<br/>Biphenyl Compounds--administration & dosage<br/>Constipation<br/>Double-Blind Method<br/>Feces<br/>Female<br/>Humans<br/>Hydroxyindoleacetic Acid--urine<br/>Irritable Bowel Syndrome--complications<br/>Male<br/>Middle Aged<br/>Pain Measurement<br/>Phenylalanine--administration & dosage<br/>Serotonin--biosynthesis<br/>Severity of Illness Index<br/>Tryptophan Hydroxylase--antagonists & inhibitors